한글목차

세계의 창상관리용 생물제제 시장은 2024년에 21억 7,000만 달러로 평가되며, 2030년까지 CAGR 6.19%로 성장하며, 31억 1,000만 달러에 달할 것으로 예측됩니다. 상처 치료용 생물제제는 생물체 또는 그 구성 성분으로부터 얻은 첨단 치료 제품으로, 신체의 고유한 치유 메커니즘을 강화하여 다양한 상처 및 조직 손상에 대한 조직 재생 및 복구를 촉진하도록 설계된 제품입니다. 이 시장을 지원하는 주요 요인으로는 특히 고령화 및 당뇨병과 같은 질병에 따른 만성 상처의 세계 증가를 들 수 있습니다.

주요 시장 성장 촉진요인

세계에서 만성 및 급성 상처 발생률이 증가함에 따라 세계 상처 관리 생물제제 시장의 기본 수요를 촉진하는 요인이 되고 있습니다. 당뇨병성 족부궤양, 욕창, 정맥성 하지궤양과 같은 병증은 복잡한 병태생리 및 치유 지연으로 인해 첨단 치료적 개입이 필요한 경우가 많습니다.

주요 시장 과제

세계 상처 치료 생물제제 시장의 성장을 저해하는 가장 큰 문제는 이러한 첨단 생물학적 치료법에 따른 높은 비용입니다. 연구개발 및 복잡한 제조 공정에 내재된 막대한 비용은 제품 가격 상승으로 직결되고 있습니다.

주요 시장 동향

개별화된 상처 관리 생물제제 솔루션의 출현은 획일적인 치료에서 개별 환자의 필요와 특정 상처 특성에 맞는 치료로 전환하는 중요한 시장 동향을 나타냅니다. 여기에는 치료 반응을 예측하고 가장 효과적인 생물제제를 선택하기 위해 바이오마커 분석 및 유전체 프로파일링과 같은 첨단 진단 기술을 활용하는 것이 포함됩니다.

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 창상관리용 생물제제 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 제품별(생물학적 피부 대체물, 외용제)
  • 창상 유형별(궤양, 외과적·외상성 창상, 화상)
  • 최종사용자별(병원, 외래 수술 센터, 화상 센터, 창상 클리닉)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 창상관리용 생물제제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 창상관리용 생물제제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 창상관리용 생물제제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 창상관리용 생물제제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 창상관리용 생물제제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병·인수
• 제품 출시
• 최근 동향

제13장 세계의 창상관리용 생물제제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Smith & Nephew Plc
• Integra LifeSciences Corporation
• Wright Medical Group N.V.
• MiMedx Group, Inc.
• Vericel Corporation
• Osiris Therapeutics, Inc.
• Organogenesis Holdings Inc.
• Solsys Medical, LLC
• Lavior Pharma Inc.
• Marine Polymer Technologies, Inc.

제16장 전략적 제안

제17장 조사회사 소개·면책사항

영문목차

The Global Wound Care Biologics Market, valued at USD 2.17 Billion in 2024, is projected to experience a CAGR of 6.19% to reach USD 3.11 Billion by 2030. Wound care biologics are advanced therapeutic products derived from living organisms or their components, engineered to augment the body's intrinsic healing mechanisms, facilitating tissue regeneration and repair for various wounds and tissue injuries. Key drivers supporting this market include the increasing global prevalence of chronic wounds, particularly those associated with an aging population and conditions such as diabetes.

Key Market Drivers

The increasing global incidence of chronic and acute wounds represents a fundamental demand driver for the Global Wound Care Biologics Market. Conditions such as diabetic foot ulcers, pressure ulcers, and venous leg ulcers often require advanced interventions due to their complex pathology and delayed healing. The prevalence of these challenging wounds creates a substantial patient population seeking effective therapeutic solutions.

Key Market Challenges

A significant challenge impeding the growth of the Global Wound Care Biologics Market is the elevated cost associated with these advanced biological therapies. The substantial expenses inherent in their research, development, and complex manufacturing processes directly translate into high product pricing. This elevated cost restricts patient access, especially in healthcare systems with stringent budget limitations or where individual out-of-pocket expenses become prohibitive. Furthermore, it introduces considerable complexities in obtaining favorable reimbursement from payers, as these entities often require extensive evidence of superior cost-effectiveness compared to existing, less expensive treatments.

Key Market Trends

The emergence of personalized wound care biologics solutions represents a pivotal market trend, moving away from uniform treatments to therapies tailored to individual patient needs and specific wound characteristics. This involves employing advanced diagnostics, such as biomarker analysis and genomic profiling, to predict therapeutic responses and guide the selection of the most effective biologic agents. This tailored approach aims to enhance treatment efficacy, reduce healing times, and optimize healthcare resource allocation by ensuring appropriate therapy application.

Key Market Players

• Smith & Nephew Plc
• Integra LifeSciences Corporation
• Wright Medical Group N.V.
• MiMedx Group, Inc.
• Vericel Corporation
• Osiris Therapeutics, Inc.
• Organogenesis Holdings Inc.
• Solsys Medical, LLC
• Lavior Pharma Inc.
• Marine Polymer Technologies, Inc.

Report Scope:

In this report, the Global Wound Care Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Wound Care Biologics Market, By Product:

• Biologic Skin Substitutes
• Topical Agents

Wound Care Biologics Market, By Wound Type:

• Ulcers
• Surgical and Traumatic Wounds
• Burns

Wound Care Biologics Market, By End User:

• Hospitals
• ASCs
• Burn Centers
• Wound Clinics

Wound Care Biologics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Wound Care Biologics Market.

Available Customizations:

Global Wound Care Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Wound Care Biologics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Biologic Skin Substitutes, Topical Agents)
  • 5.2.2. By Wound Type (Ulcers, Surgical and Traumatic Wounds, Burns)
  • 5.2.3. By End User (Hospitals, ASCs, Burn Centers, Wound Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Wound Care Biologics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Wound Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Wound Care Biologics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Wound Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Wound Care Biologics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Wound Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Wound Care Biologics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Wound Type
      • 6.3.3.2.3. By End User

7. Europe Wound Care Biologics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Wound Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Wound Care Biologics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Wound Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Wound Care Biologics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Wound Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Wound Care Biologics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Wound Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Wound Care Biologics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Wound Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Wound Care Biologics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Wound Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Wound Care Biologics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Wound Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Wound Care Biologics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Wound Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Wound Care Biologics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Wound Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Wound Care Biologics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Wound Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Wound Care Biologics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Wound Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Wound Care Biologics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Wound Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Wound Care Biologics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Wound Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Wound Care Biologics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Wound Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Wound Care Biologics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Wound Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Wound Care Biologics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Wound Type
      • 9.3.3.2.3. By End User

10. South America Wound Care Biologics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Wound Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Wound Care Biologics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Wound Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Wound Care Biologics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Wound Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Wound Care Biologics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Wound Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Wound Care Biologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Smith & Nephew Plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Integra LifeSciences Corporation
• 15.3. Wright Medical Group N.V.
• 15.4. MiMedx Group, Inc.
• 15.5. Vericel Corporation
• 15.6. Osiris Therapeutics, Inc.
• 15.7. Organogenesis Holdings Inc.
• 15.8. Solsys Medical, LLC
• 15.9. Lavior Pharma Inc.
• 15.10. Marine Polymer Technologies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer